KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Receivables (2016 - 2025)

Exact Sciences (EXAS) has disclosed Receivables for 11 consecutive years, with $298.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 8.65% to $298.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $298.7 million through Dec 2025, up 8.65% year-over-year, with the annual reading at $298.7 million for FY2025, 8.65% up from the prior year.
  • Receivables for Q4 2025 was $298.7 million at Exact Sciences, down from $337.9 million in the prior quarter.
  • The five-year high for Receivables was $386.0 million in Q2 2025, with the low at $158.0 million in Q4 2022.
  • Average Receivables over 5 years is $252.7 million, with a median of $252.9 million recorded in 2021.
  • The sharpest move saw Receivables surged 82.89% in 2021, then fell 27.05% in 2022.
  • Over 5 years, Receivables stood at $216.6 million in 2021, then fell by 27.05% to $158.0 million in 2022, then soared by 55.23% to $245.3 million in 2023, then rose by 12.04% to $274.9 million in 2024, then rose by 8.65% to $298.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $298.7 million, $337.9 million, and $386.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.